Biotech | December 15, 2021
Aragen Life Sciences acquires Intox
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Biocon Biologics and Viatris co-developed the products
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Subscribe To Our Newsletter & Stay Updated
